Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

by Gillies Stephen D, Kovar Andreas, Gooding William, Whiteside Theresa L, Atkins Michael B, Kirkwood John M, Ribas Antoni, Kashala Oscar, Morse Michael A
Published 2009-07-01